Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LABTBullishIndustry Newsnews

High materiality8/10

Lakewood-Amedex Reports Preclinical Safety Data Guiding Nu-3 Phase 2a Trial

Jul 15, 2026, 8:06 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive safety signals and explicit dose-optimization planning reduce development risk for Nu-3; raises probability of Phase 2a progression, a potential near-term stock catalyst in a thinly traded biotech name.

AI summary

What happened, with direct paths to the underlying reporting

Lakewood-Amedex Biotherapeutics disclosed robust preclinical safety data for Nu-3 gel, revealing very low systemic exposure and good tolerability. The company intends a Phase 2a trial in infected diabetic foot ulcers, testing 2%, 5%, and 10% gel concentrations to inform efficacy and safety. Positive safety signals could de-risk development and attract investor interest ahead of trial initiation.

Nu-3 gel shows safety in preclinical studies with very low systemic exposure.
Phase 2a in infected diabetic foot ulcers planned; dose levels 2%, 5%, 10%.
Safety data: well tolerated at higher doses; supports therapeutic index for topical use.
Topical Nu-3 aims to reduce systemic side effects versus traditional antibiotics.
Management anticipates Phase 2a initiation soon; regulatory alignment still a factor.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Lakewood-Amedex Reports Preclinical Safety Data Guiding Nu-3 Phase 2a Trial

Lakewood-Amedex's Nu-3 Advances Toward Phase 2 Clinical Trials